by Leanne Talbot | May 28, 2021
Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month. Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause of... by Leanne Talbot | May 25, 2021
Neuroendocrine Cancer UK is excited to announce that its publication “Patient Perspectives, from Diagnosis Through Treatments and Beyond”, co-authored by Catherine Bouvier and Nicola Jervis, has been published in Current Opinion in Endocrine and Metabolic Research... by Leanne Talbot | May 11, 2021
Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause of Merkel cell carcinoma (MCC) is not known. Factors strongly... by Leanne Talbot | Apr 21, 2021
21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC. Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults... 
